Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
Google builds an AI system that generates scientific hypotheses — and some are proving correct

Google builds an AI system that generates scientific hypotheses — and some are proving correct

New Capabilities

A multi-agent AI tool built on Gemini 2.0 independently reproduced a decade of microbiology research in 48 hours, raising questions about how science gets done

January 7th, 2026: AI Co-Scientist validated results published in peer-reviewed journals

Overview

Updated May 30

Google released an AI system in February 2025 that proposes original hypotheses and refines them through internal debate among six specialized AI agents. The system reproduced a decade-long Imperial College London study on how antibiotic-resistance genes spread between bacterial species in 48 hours, without accessing their unpublished findings.

The tool, called the AI Co-Scientist, has since produced drug-repurposing candidates for liver fibrosis and acute myeloid leukemia that passed initial laboratory validation. Generating hypotheses has long been considered the core intellectual act of science. What happens when machines can generate hypotheses as fast, and sometimes as accurately, as human experts?

Why it matters

If AI can reliably generate valid scientific hypotheses, the bottleneck in research shifts from ideas to laboratory capacity.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Play on this story Voices Debate Predict Timeline Connections

Key Indicators

48 hours
Time to match a decade of research
The AI Co-Scientist independently reproduced Imperial College London's unpublished findings on antibiotic resistance gene transfer in two days
6
Specialized AI agents in the system
The tool uses generation, reflection, ranking, evolution, proximity, and meta-review agents coordinated by a supervisor
3
Lab-validated discoveries so far
Drug candidates for liver fibrosis, acute myeloid leukemia, and an antimicrobial resistance mechanism have all been confirmed experimentally
p < 0.01
Statistical significance of drug results
Both AI-suggested drug repurposing candidates for liver fibrosis showed statistically significant anti-fibrotic activity in human organoids

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

Play

Exploring all sides of a story is often best achieved with Play.

Most of these play right now — no account needed. Sign up to save scores, keep a streak, and unlock Debate and Predict. Log in Sign Up
Predict 4 ways this could play out. Back the one you believe — contrarian picks score more when a scenario has a resolution date. Log in to play

People Involved

Demis Hassabis
Demis Hassabis
Chief Executive Officer, Google DeepMind
Leading Google's AI-for-science strategy
 Jose Penades
Jose Penades
Professor of Microbiology, Imperial College London
Validated AI Co-Scientist's antimicrobial resistance hypothesis

Organizations Involved

Google DeepMind
Google DeepMind
AI research and product division
Developer and operator of the AI Co-Scientist

Alphabet's primary artificial intelligence research division, responsible for AlphaFold, AlphaGo, Gemini, and the AI Co-Scientist.
Isomorphic Labs
Isomorphic Labs
AI Drug Discovery Company
Advancing AI-designed drug candidates toward clinical trials

An Alphabet subsidiary applying AI to pharmaceutical research, aiming to bring its first AI-designed drug candidate into clinical trials.

Timeline

November 2020 January 2026

9 events Latest: January 7th, 2026 · 8 months ago
Tap a bar to jump to that date

  1. AI Co-Scientist validated results published in peer-reviewed journals

    Latest Validation

    Drug repurposing results generated by the AI Co-Scientist for liver fibrosis are published in Advanced Science, with the FDA-approved cancer drug vorinostat confirmed as showing significant anti-fibrotic activity in human hepatic organoids. The tool moves from demonstration to published, peer-reviewed science.

  2. Microsoft enters AI-for-science race with Discovery platform

    Competition

    Microsoft announces its own enterprise agentic platform for accelerating scientific research, including tools for materials discovery and protein engineering, broadening the competitive landscape.

  3. Sakana AI releases fully autonomous AI Scientist v2

    Competition

    Japanese startup Sakana AI releases a competing system that goes further than Google's collaborative approach, generating entire research papers autonomously for roughly $15 each. One such paper later becomes the first fully AI-generated work to pass rigorous human peer review.

  4. Scientists push back on 'co-scientist' framing

    Criticism

    TechCrunch publishes expert responses questioning whether the tool truly generates novel hypotheses or recombines existing knowledge, and whether automating hypothesis generation diminishes the core intellectual work of science.

  5. Google announces the AI Co-Scientist

    Launch

    Google introduces the AI Co-Scientist, a multi-agent system built on Gemini 2.0 that generates and refines scientific hypotheses. The announcement includes a Trusted Tester Program for research organizations worldwide and details three validated discoveries.

  6. Imperial College London confirms AI matched decade of research

    Validation

    Microbiologists Jose Penades and Tiago Costa reveal that the AI Co-Scientist independently reproduced their unpublished findings on how antibiotic-resistance genes spread between bacterial species — a mechanism their team spent ten years proving experimentally.

  7. OpenAI launches Deep Research

    Competition

    OpenAI releases its own AI research tool, Deep Research, weeks before Google's announcement, intensifying the race to build AI systems that can assist with scientific inquiry.

  8. Hassabis and Jumper win Nobel Prize for AlphaFold

    Recognition

    The Nobel Committee awards the Chemistry prize to Demis Hassabis and John Jumper for AlphaFold's contributions to computational protein structure prediction, validating AI-driven scientific research at the highest level.

  9. AlphaFold 2 solves the protein-folding problem

    Milestone

    Google DeepMind's AlphaFold 2 demonstrates it can predict protein structures with near-experimental accuracy, solving a 50-year grand challenge in biology and establishing AI as a serious tool for scientific discovery.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

2013-2018

IBM Watson for Oncology disappointment (2013-2018)

IBM marketed Watson as an AI system that could recommend cancer treatments by analyzing patient records and medical literature. Over five years, hospitals in the United States, India, South Korea, and elsewhere deployed it. Internal IBM documents later revealed the system frequently made unsafe and incorrect treatment recommendations, and its training relied heavily on a small number of doctors at Memorial Sloan Kettering rather than broad medical evidence.

Then

Several hospitals abandoned Watson for Oncology. IBM's healthcare AI division lost credibility and was eventually sold to Francisco Partners in 2022 for roughly $1 billion — a fraction of the estimated $4 billion IBM had invested.

Now

Watson became shorthand for the gap between AI marketing and AI reality in healthcare. It raised lasting questions about validation standards for AI systems making scientific or medical recommendations.

Why this matters now

The AI Co-Scientist faces the same fundamental challenge Watson did: proving that AI-generated scientific recommendations are reliable enough to act on. Google's strategy of publishing validated results in peer-reviewed journals and running a Trusted Tester Program suggests it learned from Watson's failure to establish credibility through rigorous, independent validation rather than marketing claims.

November 2020

AlphaFold solves protein folding (2020)

Google DeepMind's AlphaFold 2 demonstrated it could predict protein 3D structures with near-experimental accuracy at the Critical Assessment of protein Structure Prediction (CASP14) competition. The protein-folding problem — predicting a protein's shape from its amino acid sequence — had been an open grand challenge in biology for 50 years. By 2022, DeepMind had published predicted structures for nearly every known protein, roughly 200 million structures.

Then

Structural biologists gained instant access to protein structures that would have taken years to determine experimentally. Drug designers could model molecular interactions without waiting for lab results.

Now

AlphaFold established AI as a legitimate tool for fundamental scientific discovery, not just data analysis. Hassabis and Jumper received the 2024 Nobel Prize in Chemistry, and the success became the template for Google's broader AI-for-science ambitions.

Why this matters now

The AI Co-Scientist is a direct extension of the approach that worked with AlphaFold — applying AI to a well-defined scientific problem — but generalized from protein structure to hypothesis generation across all domains. AlphaFold's success gave Google both the credibility and the organizational confidence to attempt this much broader challenge.

November 2022

Meta's Galactica launch and withdrawal (2022)

Meta's AI research division released Galactica, a large language model trained on over 48 million scientific papers, textbooks, and datasets. It was designed to summarize literature, solve math problems, and generate scientific text. Within three days of public release, researchers demonstrated it confidently generated racist content and scientifically inaccurate text presented as fact. Meta pulled the public demo.

Then

The withdrawal embarrassed Meta and fueled skepticism about applying large language models to scientific research. Critics argued that plausible-sounding but wrong scientific text was more dangerous than obviously wrong text.

Now

The incident established a cautionary template for AI-in-science tools: the ability to generate fluent scientific prose doesn't mean the content is correct. It pushed subsequent efforts, including Google's, toward architectures with built-in verification and self-critique rather than simple text generation.

Why this matters now

Google's multi-agent design — with dedicated reflection, ranking, and meta-review agents that critique and challenge the generation agent's output — directly addresses the failure mode that sank Galactica. The AI Co-Scientist's architecture is partly an answer to the question: how do you prevent an AI from being confidently wrong about science?

Sources

(12)
+6
Human Progress Google Research Blog arXiv TechCrunch Imperial College London IEEE Spectrum Advanced Science Nature Sakana AI InfoQ European Journal of Cardiovascular Nursing TechCrunch